abstract |
The present invention intends to provide a novel monoclonal antibodynhaving a binding specificity to GALP or its derivative, which is useful inndeveloping therapeutic agents, preventive agents or diagnostic agent for diseasesnassociated with GALP or its derivative, and a method of quantifying GALP usingnthe antibody. More specifically, the present invention provides an antibodynspecifically reacting with a partial peptide in the C-terminal region of a polypeptidenhaving the amino acid sequence represented by SEQ ID NO: 1, SEQ ID NO: 2 ornSEQ ID NO: 3, or its derivative, and a method of quantifying GALP or itsnderivative. |